De Raaf MA, Beekhuijzen M, Guignabert C, et al: Endothelin-1 receptor antagonists in fetal development and pulmonary arterial hypertension. Reprod Toxicol 56:45, 2015 Del Campo M, Kosaki K, Bennett FC, et al: Developmental delay in fetal aminopterin/ methotrexate syndrome. Teratology 60( 1): 10, 1999 Di Sessa TG, Moretti ML, Khoury A, et al: Cardiac function in fetuses and newborns exposed to low-dose aspirin during pregnancy. Am J Obstet GynecoIo171(4):892,o1994 Dolk H, Loane M, Garne E: The prevalence of congenital anomalies in Europe. Adv Exp Med BioI 686:349, 2010 D'Souza SW, Black P, Richards B: Smoking in pregnancy: associations with skinfold thickness, maternal weight gain, and fetal size at birth. BMJ 282(6227):1661, 1981 Ehrenstein V, Sorensen HT, Bakketeig LS, et al: Medical databases in studies of drug teratogenicity: methodological issues. Clin EpidemioIo2(1):37, 2010 Enns GM, Roeder E, Chan RT, et al: Apparent cyclophosphamide (Cytoxan) embryopathy: a distinct phenotype? Am J Med Genet 86(3):237, 1999
Eze N, Smith LM, LaGasse LL, et al: School-aged outcomes following prenatal methamphetamine exposure: 7.5-year follow-up from the infant development, environment, and lifestyle study. J Pediatr 170:34.e1, 2016 Feldkamp M, Carey JC: Clinical teratology counseling and consultation case report: low dose methotrexate exposure in the early weeks of pregnancy. Teratology 47(6):533, 1993 Feldkamp ML, Carey Jc, Byrne JL, et al: Etiology and clinical presentation of birth defects: population based study. BMJ 357:j2249, 2017 Finnegan LP, Connaughton JF, Kron E et al: Neonatal abstinence syndrome: assessment and management. Addict Dis 2(1-2):141, 1975 Fisher SC, Van Zutphen AR, Werler MM, et al: Maternal antihypertensive medication use and congenital heart defects: updated results from the National Birth Defects Prevention Study. Hypertension 69(5):798,o2017 Food and Drug Administration: Advice about eating fish, from the Environmental Protection Agency and Food and Drug Administration; revised fish advice; availability. Federal Register 82(12):6571, 2017a Food and Drug Administration: Antipsychotic drug labels updated on use during pregnancy and risk of abnormal muscle movements and withdrawal symptoms in newborns. 2011. Available at: http://www.fda.gov/Drugs/ DrugSafety/ucm243903.htm. Accessed September 24, 2017 Food and Drug Administration: Content and format of labeling for human prescription drug and biological products; requirements for pregnancy and lactation labeling. Final rule. Fed Regist 79(233):72036,o2014
Food and Drug Administration: Pregnancy registry information for health professionals.
b. Available at: https:!lwww.fda.gov/ScienceResearch/ SpecialT opics/WomensHealthResearchl ucm256789 .hnn. Accessed September 24,s2017